Vical’s Phase 1/2 Trial Data Presented at ASM 2016 Shows Bivalent Vaccine Imparts Reduction in Genital Herpes Lesions Durable to 9 Months
June 20, 2016 11:15 ET
|
Vical Incorporated
SAN DIEGO, June 20, 2016 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) presented data from the randomized, double-blind, placebo-controlled Phase 1/2 clinical trial of its therapeutic...
Vical to Present HSV-2 Phase 1/2 Data at June ASM Microbe/ICAAC 2016 Conference
June 13, 2016 06:30 ET
|
Vical Incorporated
SAN DIEGO, June 13, 2016 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company will present clinical data on its completed HSV-2 Phase 1/2 trial at the American...
Vical Provides VL-2397 Updates at BIO International Convention
May 31, 2016 06:30 ET
|
Vical Incorporated
SAN DIEGO, May 31, 2016 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company will present an update on its investigational antifungal product candidate, VL-2397,...
Vical Reports First Quarter 2016 Financial Results
May 09, 2016 06:30 ET
|
Vical Incorporated
ASP0113 Phase 3 Trial Enrollment Over 80% Complete HSV-2 Data to be presented at June ASM Microbe/ICAAC 2016 Conference SAN DIEGO, May 09, 2016 (GLOBE NEWSWIRE) -- Vical Incorporated...
Vical Announces News Release and Conference Call Schedule for First Quarter 2016 Financial Results
May 02, 2016 06:30 ET
|
Vical Incorporated
SAN DIEGO, May 02, 2016 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months ended March 31, 2016, before the...
FDA Grants Vical Fast Track Designation for VL-2397 for the Treatment of Invasive Aspergillosis
March 30, 2016 06:30 ET
|
Vical Incorporated
SAN DIEGO, March 30, 2016 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL), a biotechnology company developing vaccines and therapeutics for prevention and treatment of infectious diseases,...
Vical Reports Fourth Quarter 2015 Financial Results
March 14, 2016 06:30 ET
|
Vical Incorporated
Futility Analyses Completed on CMV Phase 3 Trial in HCT Patients and Trial Continuing as Planned Phase 1 Trial Initiated for Novel Antifungal SAN DIEGO, March 14, 2016 (GLOBE NEWSWIRE) -- ...
Vical to Present at the 28th Annual ROTH Conference
March 09, 2016 06:00 ET
|
Vical Incorporated
SAN DIEGO, March 09, 2016 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on...
Vical Announces News Release and Conference Call Schedule for Fourth Quarter 2015 Financial Results
March 07, 2016 16:05 ET
|
Vical Incorporated
SAN DIEGO, March 07, 2016 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three and twelve months ended December 31,...
Vical Initiates Phase 1 Trial of Novel Antifungal Compound VL-2397
March 07, 2016 06:30 ET
|
Vical Incorporated
SAN DIEGO, March 07, 2016 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the initiation of a Phase 1 clinical trial of the company’s novel antifungal, VL-2397. The...